
Opinion|Videos|August 14, 2024
Monitoring Response in Immune Checkpoint Inhibitor-Based RCC Therapy
Medical experts examine strategies for monitoring treatment response in patients initiating first-line immune checkpoint inhibitor-based therapy for metastatic renal cell carcinoma.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Dr Hans Lee on the Game-Changing Myeloma Research From ASH 2025
3
Nadunolimab Misses Efficacy Mark in TNBC, Despite Strong OS
4
The Targeted Pulse: Blood and Breast Cancer News
5







































